CD40 and neoplasm: In this publication, we report the screening of several formats of antagonist anti-PDL1 sdAb as well as CD40 or 4-1BB agonist constructions that were tested in the context of tumor cells infected by an oncolytic vaccinia virus to select the most effective payloads for each pathway.